News | March 29, 2025
Curium completes acquisition of Monrol
Positions Curium as leading manufacturer of Lu-177 isotope
Positions Curium as leading manufacturer of Lu-177 isotope
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Subscribe To Our Newsletter & Stay Updated
